8-K: Bausch + Lomb Reports Strong Q4 and Full-Year 2024 Results, Issues Positive 2025 Guidance

Bausch + Lomb announced a 9% revenue increase for Q4 2024 and a 16% increase for the full year, driven by growth across all segments and providing a positive outlook for 2025.

Summary

• Bausch + Lomb reported Q4 2024 revenue of $1.280 billion, a 9% increase compared to Q4 2023, or 11% on a constant currency basis.
• The company's GAAP net loss attributable to Bausch + Lomb Corporation was $3 million for Q4 2024.
• Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) was $259 million for Q4 2024.
• Full-year 2024 revenue reached $4.791 billion, a 16% increase compared to 2023, or 17% on a constant currency basis.
• The full-year GAAP net loss attributable to Bausch + Lomb Corporation was $317 million.
• Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) for the full year was $878 million.
• The company's 2025 financial outlook includes revenue between $4.950 billion and $5.050 billion, representing approximately 5.5% to 7.5% constant currency growth.
• Full-year Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) is projected to be between $900 million and $950 million for 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong revenue growth and positive guidance, but tempered by the GAAP net loss and risks associated with the separation plan.

Positives

• Revenue grew across all segments and geographies.
• The dry eye portfolio is performing strongly, approaching $1 billion in annual revenue.
• The contact lens business is experiencing double-digit revenue growth.
• The surgical portfolio is expanding with growth across all product categories.
• Key consumer franchises, including LUMIFY and eye vitamins, achieved solid growth.
• The company is transforming its R&D pipeline and making strategic investments, including the acquisition of Elios Vision.
• Cash flow from operations increased by $249 million for the full year of 2024.

Negatives

• The company reported a GAAP net loss attributable to Bausch + Lomb Corporation of $3 million for Q4 2024.
• The company reported a GAAP net loss attributable to Bausch + Lomb Corporation of $317 million for the full year of 2024.
• Adjusted EPS attributable to Bausch + Lomb Corporation for the full year of 2024 was $0.58 as compared to $0.73 for the full year of 2023.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those discussed in Bausch + Lomb's filings with the SEC and the CSA.
• Risks and uncertainties exist regarding the proposed plan to separate Bausch + Lomb into an independent, publicly traded company.
• Adverse economic conditions and macroeconomic factors, including heightened inflation and interest rates, could negatively impact the company's revenue, expenses, and margins.

Future Outlook

Bausch + Lomb expects full-year 2025 revenue to be between $4.950 billion and $5.050 billion, representing approximately 5.5% to 7.5% constant currency growth, and Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) to be between $900 million and $950 million.

Management Comments

• Underpinning our recent success is a commitment to long-term, profitable growth, said Brent Saunders, chairman and CEO, Bausch + Lomb.
• Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs.

Industry Context

The eye health market is competitive, with companies like Alcon, Johnson & Johnson Vision, and CooperVision also vying for market share. Bausch + Lomb's focus on innovation and strategic acquisitions, such as Elios Vision and XIIDRA, positions it to compete effectively in this space.

Comparison to Industry Standards

• Bausch + Lomb's revenue growth of 16% for the full year of 2024 is strong compared to the overall growth rate of the eye care market.
• Alcon, a major competitor, reported a revenue increase of 8.2% in 2023.
• Johnson & Johnson Vision's performance varies by segment, but Bausch + Lomb's growth in contact lenses and surgical products appears competitive.
• The adjusted EBITDA margin of Bausch + Lomb is in line with industry standards.

Stakeholder Impact

• Shareholders can expect continued growth and potential value creation.
• Employees will benefit from the company's growth and strategic investments.
• Customers will have access to innovative eye health products and services.
• Suppliers will benefit from the company's increased demand for materials and services.
• Creditors will be reassured by the company's strong financial performance and positive outlook.

Next Steps

• The company will continue to focus on driving growth across all segments.
• Bausch + Lomb will continue to transform its R&D pipeline and make strategic investments.
• The company will execute its 2025 financial outlook.

Key Dates

Keywords

revenue, Bausch + Lomb, financial results, EBITDA, eye health, guidance, 2024, 2025